SOLID TUMOR, ADULT

This trial tests a new genetic vaccine called Nous-209, combined with the drug pembrolizumab, in adults with specific types of cancer that have a genetic flaw called MSI-H or dMMR. The cancers studied include colorectal, stomach, and gastro-esophageal junction tumors that cannot …

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This early-phase study tests an experimental drug called KIN-2787 in about 400 adults with advanced solid tumors (including lung cancer and melanoma) that have specific BRAF or NRAS gene mutations. The main goals are to check safety, find the best dose, and see if the drug can sh…

This early-phase trial tests a custom-made vaccine using a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given together with two immunotherapy drugs to boost the immune system's attack on tumors. The study includ…

This early-phase trial tests a new drug called IOS-1002, given alone or with pembrolizumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 140 …

This early-phase study tests an experimental drug called DECOY20, given alone or with another drug (tislelizumab), in about 120 adults with advanced solid tumors like liver, colorectal, pancreatic, lung, head and neck, bladder, or MSI-high cancers. The main goals are to check saf…

This study tests an experimental drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors. About 310 adults whose cancer has not respon…

This early-phase study tests a new drug called IMA401 in about 95 adults with advanced solid tumors (like lung or head/neck cancer) that came back or didn't respond to prior treatments. IMA401 is a special immune molecule that helps the body's T cells attack cancer cells. The stu…

This study tests a new drug called ICT01, given alone or with the immunotherapy Keytruda, in people with advanced solid tumors or blood cancers that have come back or not responded to treatment. The goal is to see if ICT01 is safe and can help control the cancer by activating a s…

This study tests a new proton therapy machine called PROTEUS® PLUS in 47 adults with solid tumors. The goal is to see if it is safe and effective at controlling cancer. Researchers will measure tumor response and track side effects.

This early-phase study tests a personalized immunotherapy called MVX-ONCO-2 in 6 adults with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The m…

This early-stage study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. Participa…

This study tests a new drug called visugromab (CTL-002) in people with advanced solid tumors that have stopped responding to standard treatments. The drug is given alone or together with an approved immunotherapy. The goal is to see if it is safe and can help shrink tumors. About…

This study tests a new proton therapy machine (PROTEUS® PLUS) in 47 adults with solid tumors. The goal is to see if it safely controls tumor growth and reduces side effects compared to standard radiation. Participants receive targeted proton beams to shrink or stabilize their can…

This study tests a new proton therapy machine (PROTEUS® PLUS) in 47 adults with solid tumors. The goal is to see if it safely controls tumor growth. Participants receive targeted radiation, and researchers track side effects and disease response over time.

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers, including solid tumors, lymphoma, lung cancer, melanoma, and myelofibrosis. The main goal is to check if the drug is safe and tolerable, and to see if it can boost the …

This study tests whether benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The drug works by lowering eosinophil levels in the blood. About 51 adults with solid tumors or blood cancers who have moderate to severe skin reactions are…

This study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if this could help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid t…

This study follows people with different cancers who have already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.